SWOG clinical trial number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Open
Phase
II-III
Abbreviated Title
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Status Notes
This study is open to accrual on December 21, 2021.
Activated
12/21/2021

Research committees

Lung Cancer

Treatment

Carboplatin Pemetrexed Ipilimumab Nivolumab Paclitaxel Pembrolizumab

Eligibility Criteria Expand/Collapse

SWOG Cancer Research Network has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.



Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2022

Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer

S Schild;X Wang;C Bestvina;T Williams;G Masters;A Singh;T Stinchcombe;J Salama;S Wolf;T Zemla;N Duma;S Chun;A Amini;D Kozono;C Watt Clinical Lung Cancer Apr 30;S1525-7304(22)00065-1. doi: 10.1016/j.cllc.2022.04.004. Online ahead of print

PMid: PMID35613998

Other Clinical Trials